Abstract Library
Members may log into MY ENETS to visit the abstract library from previous ENETS conferences.
Participants of the ENETS Conference in 2024 can now access the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more via My ENETS.
ENETS Abstract Search
Introduction: QLQ-GINET21 for pts with GI-NETs covers muscle/bone pain, body image, information, sexual function, symptoms, social function and disease-related concerns.
Conference: 15th Annual ENETSConcerence (2018)
Presenting Author:
Authors: Gallego J, Reig O, Sastre J, Garcia I, Segura A,
Keywords: neuroendocrine tumors, Quality of Life, QLQ-GINET21, utility,
Introduction: Outcome measures reported by pts help to weigh benefit/effect of a therapy on quality of life (QoL), provided that their utility in clinical practice is proved. There are few QoL QNRs for pts with NETs, like QLQ-GINET21, with 21 items assessing muscle/bone pain, body image, information, sexual function, symptoms, social function and disease-related concerns.
Conference: 14th Annual ENETSConcerence (2017)
Presenting Author: Gallego J
Authors: Gallego J, Benavent M, Reig �, Sastre J, Díaz-Pabón I,
Keywords: neuroendocrine tumors, QoL, QLQ-GINET21, utility,
Introduction: Sorafenib (S) and bevacizumab (B) as single agents have shown efficacy and acceptable toxicity in NETs phase II trials. S+B combination has shown manageable toxicity in phase I trials in solid tumors.
Conference: 8th Annual ENETSConcerence (2011)
Presenting Author:
Authors: Castellano D, Capdevila J, Salazar R, Sastre J, Alonso V,
Keywords: targeted therapy, sorafenib, bevacizumab,